Pediatrics

Pediatric keratoconus is often more challenging to diagnose, resulting in treatment delay and vision loss.

A recent study found that the use of low-dose atropine drops is ineffective in slowing pediatric myopia progression, contradicting a previous study.

These free eye screenings, exams, and prescription glasses during the third annual program at Hands in 4 Youth Camp Vacamas are in thanks to the partnership of Jonas Philanthropies and Vision to Learn.

Studies suggest that high glycemic load carbohydrate diets may alter the genetic influence of growth of the sclera and choroid, which ultimately can induce permanent changes in the development and progression of myopia.

Optometrists should be aware of the consequences of digital device use beyond myopia.

Investigators reported “an increasing trend in the incidence of eye injuries associated with so-called ‘nonpowder’ guns among children.”

Although the use of atropine is not necessarily novel in the myopia management world, the fact that practitioners may soon have an FDA approved formulation of atropine is new and exciting.

In this recent study, Bharti Nihalani-Gangwani, MD, and Deborah VanderVeen, MD, reported that 29% developed glaucoma in a large infant cohort and the risk factors at the American Society of Cataract and Refractive Surgery annual meeting in San Diego.

New research suggests sleep is an additional risk factor affecting myopia onset and progression.

The study found that pseudophakic children older at the time of surgery developed a glaucoma-related adverse event less frequently.

In a sham device-controlled, randomized, double-blind clinical trial in China, researchers utilized a device that emits 650 nm red light directly to the retina.

Pediatric glaucoma, although rare, can cause irreversible vision loss and leave children visually impaired if not treated timely and adequately.

Although the 20-20-20 rule is still a solid recommendation, recent studies have provided practitioners with more specific recommendations to help potentially prevent the onset and slow the progression of myopia.

A look back on what happened in optometry during the week of March 20-March 24.

REACH operates with three objectives: 1) eliminate barriers to eye health for school children; 2) improve the quality of school eye health services; and 3) create a positive, sustainable environment at schools where eye health services are provided, ensuring children feel comfortable to access these services.

Ashley Wallace-Tucker, OD, FAAO, FSLS, Dipl ABO, shares key takeaways from her SECO 2023 panel discussion, "Myopia management."

Aflibercept, a VEGF inhibitor previously indicated for a variety of retinal diseases, is the first pharmacological treatment for retinopathy of prematurity in preterm infants.

Protecting children’s eye health will demand a focus on vision and learning through better nutrition, myopia management, and disease prevention.

Second global virtual event on myopia management scheduled for February 16, 2023.

As our dependence on technology progresses, we have seen tremendous impact on all aspects of our lives—including our kids’ eyes and vision.

As 2022 comes to a close, check out some of the hottest and most-liked stories from the year!

Three experts in myopia control convened at the Optometry Times EyeCon meeting to discuss methods to control this burgeoning global epidemic.

The submission is supported by positive phase 3 data, which shows quick reversal of dilation and favorable safety and tolerability.

The #GlassesOn campaign promotes the benefits of eyewear for kids and invites support for the non-profit through Giving Tuesday on November 29th.

Research indicates that too much technology usage results in negative effects on eyesight.

Enhanced treatments, tools, and resources make a difference.

Contact lenses can be beneficial for children, even when not medically necessary, explains Jennifer Fogt, OD, FAAO, FSLS.

Christina Twardowski, OD, FAAO, and Erin D. Stahl, MD, share highlights from their discussion titled, "A collaborative approach to pediatric keratoconus," which they presented during the 2022 American Academy of Optometry meeting.

Awareness of visual impairment in clinical practice is suboptimal, and adherence to ophthalmologic evaluation needs to be improved. The prospective cohort study in the Netherlands included 170 children aged 0 to 18 years with a newly diagnosed brain tumor.

Clinical pilot study evaluates effect after 1 month of wear.